According to Bristol-Myers Squibb CEO Lamberto Andreotti, the company will continue to pursue its strategy of developing innovative prescription drugs rather than diversifying as other pharmaceutical companies have done, the Financial Times reported Monday. Andreotti, who replaced James Cornelius in May, said he plans to "not give up the big pharma legacy, and combine it with what’s good in biotech," adding that he would pursue "selective integration," as well as partnerships to share risk, cost and expertise. "We are not going to do everything ourselves," he noted.
Reference Articles
Bristol-Myers Squibb continues tradition - (Financial Times)
**Published in "First Word"
No comments:
Post a Comment